MO HB1685

Allows eligible terminal illness patients to access investigational drugs, biological products, or devices that have completed Phase 1 clinical trials but are not yet FDA-approved, excluding Schedule I controlled substances.

Requires eligible patients to have exhausted all FDA-approved treatment options and relevant clinical trials in Missouri, received physician recommendation, and provided written informed consent as comprehensive as clinical trial consent.

Permits manufacturers to provide investigational drugs to eligible patients without requiring compensation, or manufacturers may charge for manufacturing costs.

Prohibits state agencies and regulatory boards from revoking or failing to renew physician licenses solely based on recommending investigational drugs to eligible patients, and prevents Medicare certification actions for this recommendation.

Provides liability protection from state law claims for persons manufacturing, prescribing, dispensing, or administering investigational drugs to eligible patients, except in cases of gross negligence or willful misconduct.